The Q2 earnings beat indicates strong financial performance by Ascendis Pharma, which is a positive signal to investors. Additionally, the royalty funding agreement with Royalty Pharma could provide the company with a steady stream of revenue, further boosting investor confidence and leading to a rise in share prices.